argenex (NASDAQ:ARGX – Free Report) had its price objective reduced by Royal Bank Of Canada from $1,100.00 to $1,025.00 in a report released on Tuesday,Benzinga reports. They currently have an outperform rating on the stock.
Other equities research analysts also recently issued reports about the company. Wells Fargo & Company boosted their price target on argenex from $1,355.00 to $1,356.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. HC Wainwright increased their price objective on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Piper Sandler increased their price objective on shares of argenex from $1,075.00 to $1,215.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Barclays reissued a “buy” rating on shares of argenex in a report on Monday, September 7th. Finally, Sanford C. Bernstein restated a “buy” rating on shares of argenex in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,148.00.
Check Out Our Latest Report on argenex
argenex Price Performance
ARGX stock opened at $875.76 on Tuesday. argenex has a 1 year low of $661.85 and a 1 year high of $1,072.75. The company has a market cap of $55.08 billion, a P/E ratio of 33.63, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44. The stock’s fifty day moving average price is $956.17 and its 200-day moving average price is $885.45.
argenex (NASDAQ:ARGX – Get Free Report) last posted its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. argenex had a return on equity of 43.59% and a net margin of 32.19%. The company had revenue of $1.75 billion during the quarter. As a group, analysts expect that argenex will post 28.71 earnings per share for the current year.
Institutional Trading of argenex
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Guardian Partners Inc. bought a new position in shares of argenex in the third quarter worth about $863,000. Sowell Financial Services LLC grew its stake in shares of argenex by 25.8% during the 3rd quarter. Sowell Financial Services LLC now owns 459 shares of the company’s stock valued at $440,000 after acquiring an additional 94 shares during the period. Pinnacle Associates Ltd. grew its stake in shares of argenex by 59.4% during the 3rd quarter. Pinnacle Associates Ltd. now owns 757 shares of the company’s stock valued at $726,000 after acquiring an additional 282 shares during the period. Diversify Advisory Services LLC grew its stake in shares of argenex by 32.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 2,911 shares of the company’s stock valued at $2,791,000 after acquiring an additional 714 shares during the period. Finally, Prime Capital Investment Advisors LLC purchased a new stake in argenex in the 3rd quarter worth approximately $236,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.
argenex Company Profile
argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.
argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.
Featured Articles
- Five stocks we like better than argenex
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
